Comparison
22q11 2 Deletion Syndrome Cn294181 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between 22q11 2 Deletion Syndrome CN294181 and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
22q11 2 Deletion Syndrome Cn294181
A genetic condition where a small piece of chromosome 22 is missing. It can affect the heart, immune system, and development. Treatment involves managing symptoms across multiple specialties.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
22q11 2 Deletion Syndrome Cn294181
0-null
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
22q11 2 Deletion Syndrome Cn294181
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
22q11 2 Deletion Syndrome Cn294181
Chronic
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
22q11 2 Deletion Syndrome Cn294181
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
22q11 2 Deletion Syndrome Cn294181
congenital
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
22q11 2 Deletion Syndrome Cn294181
genetic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
22q11-2-deletion-syndrome-CN294181 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 22q11 2 Deletion Syndrome Cn294181 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| Developmental concerns | May include developmental differences with variable congenital features. | May include neurologic or developmental effects from childhood. | Moderate |
| System involvement | Source data emphasize heart, immune system, and development. | Source data emphasize brain and nervous system. | High |
| Onset pattern | Onset range is incompletely specified as 0-null. | Reported onset range is 0-10 years. | Moderate |
When to favor each condition
Choose 22q11 2 Deletion Syndrome Cn294181 when
Congenital multisystem features
Heart, immune, or developmental findings suggest chromosomal evaluation.
Moderate
Suspected chromosomal deletion
The described mechanism is missing chromosome 22 material.
High
Severe congenital course
Supplied severity is severe, though individual course varies.
Moderate
Choose 2 Hydroxyglutarate Aciduria C5139239 when
Suspected metabolic disorder
Buildup of 2-hydroxyglutaric acid points toward metabolic testing.
High
Childhood neurologic presentation
Source data link the condition mainly to brain and nervous system.
Moderate
Onset within 0-10 years
This matches the supplied onset range better than the incomplete left range.
Low
How key tests differ
| Test | 22q11 2 Deletion Syndrome Cn294181 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| Genetic testing | May identify a chromosome 22 deletion. | Not the primary test suggested by the source description. | A positive deletion supports the left condition; absence does not exclude other diagnoses. |
| Metabolic testing | No specific metabolite pattern is established here. | May show 2-hydroxyglutaric acid accumulation. | Abnormal metabolite results require clinician confirmation and are not themselves a complete diagnosis. |
| System-directed evaluation | Cardiac and immune assessments may be relevant. | Neurologic assessment and monitoring may be relevant. | Testing should follow clinical findings; exact thresholds are not supplied. |
Prognosis comparison
22q11 2 Deletion Syndrome Cn294181
- Outcome
- Chronic and described as severe, with highly variable individual outcomes.
- Factors
- Extent of congenital, cardiac, immune, and developmental involvement.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- Chronic and described as moderate, but outcome is not definitively established.
- Factors
- Neurologic involvement and response to supportive monitoring.
Time frame: Long-term; exact survival or progression data are not supplied.
Diagnosis confirmation, affected systems, complications, and access to multidisciplinary care.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac complications | Possible because heart involvement is described. Not established by the supplied source. Do not assume cardiac disease without evaluation. |
| Immune complications | Possible because immune involvement is described. Not established by the supplied source. Infection risk and immune status need clinician assessment. |
| Neurologic complications | Developmental effects may occur, but neurologic specifics are not established. Brain and nervous-system effects are described. Severity and complications vary and are not quantified here. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other involves accumulation of a metabolic acid.
- HighSpecialist care
Both generally need coordinated monitoring; treatment details and doses are not established here.
- MediumNot contagious
Neither condition is described as communicable.